Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

GUR vs. XLV: which is better?

Bottom line

GUR vs XLV: the short answer

GUR (Spdr(r) S&P(r) Emerging Europe ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.

Updated Nov 19, 2026

GUR vs XLV side by side

GURXLV
TypeETFETF
Fund familySPDR (State Street)SPDR (State Street)
CategoryEmerging MarketsHealth Care Sector
Expense ratio—0.08%
Annual cost per $10k—$8
10-yr cost on $10k (prospectus)—$103
Max front loadNoneNone
12b-1 fee—0.02%
1-yr return—+14.5%
5-yr return (annualized)—+8.1%
10-yr return (annualized)—+9.8%
Best quarter—+14.5%
Worst quarter—−12.7%
Net assets (fund)—$40.6B
Number of holdings—65
Portfolio turnover—2%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

GUR and XLV share none of their top holdings.

GUR top 10

    XLV top 10

    1. Eli Lilly & Co — 16.51%
    2. Johnson & Johnson — 10.64%
    3. AbbVie Inc — 7.74%
    4. UnitedHealth Group Inc — 6.57%
    5. Merck & Co Inc — 5.52%
    6. Amgen Inc — 3.40%
    7. Thermo Fisher Scientific Inc — 3.24%
    8. Abbott Laboratories — 2.75%
    9. Gilead Sciences Inc — 2.73%
    10. Intuitive Surgical Inc — 2.45%

    FAQ

    What is the difference between GUR and XLV?
    GUR (Spdr(r) S&P(r) Emerging Europe ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.
    Should I own both GUR and XLV?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.